New drug combo may improve stem cell transplants for blood cancer patients
NCT ID NCT02861417
First seen Feb 19, 2026 · Last updated Apr 30, 2026 · Updated 10 times
Summary
This study tests a specific timing of chemotherapy drugs (busulfan, fludarabine, and cyclophosphamide) before and after a donor stem cell transplant in 204 people with various blood cancers. The goal is to reduce the risk of the transplant failing or causing severe side effects like graft-versus-host disease. Participants receive chemotherapy to kill cancer cells and prepare the body for donor stem cells, then cyclophosphamide after transplant to help prevent the donor cells from attacking the patient's body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.